Home-Based System Relieves Cirrhosis Refractory Ascites
|
By HospiMedica International staff writers Posted on 11 Jan 2022 |

Image: An ascites patient with abdominal paracentesis scars (Photo courtesy of iStock)
A novel tunneled peritoneal catheter (PeCa) drainage system provided significant relief for patients with refractory ascites, according to a new study.
The PeCa implant, developed at Hannover Medical School (Germany), is composed of internal shut that lies in the peritoneal cavity, a tunneled section that passes through subcutaneous tissue, and an external port to which drainage bags are connected. To test system efficacy, outcomes in 152 patients with refractory ascites, who were not candidates for transjugular intrahepatic portosystemic shunt (TIPS) and received a PeCa implant, were compared to 71 patients who received standard care, which included repeated large volume paracentesis and albumin.
The results revealed that factors associated with 90-day survival were PeCa implantation, and each point of Model for End-Stage Liver Disease (MELD) score. Hospitalizations were more common in the PeCa group, for reasons that included spontaneous bacterial peritonitis (SBP), hyponatremia, and infections other than SBP. There was no significant difference in mortality between the two groups, but there were trends in the PeCa group towards higher frequency of acute kidney injury (AKI). The study was presented at the American Association for the Study of Liver Diseases annual conference, held online during November 2021.
“Patients with refractory ascites have a very high risk for rehospitalization, AKI, and death. Our data indicate that PeCa could be a valuable new treatment option for patients with refractory ascites and contraindication for TIPS,” said study co-author and presenter Tammo Lambert Tergast, MD. “I think if we can optimize the treatment after discharge, we can also minimize the rehospitalization in these patients. However, the risk for hyponatremia and AKI has to be considered and further explored.”
Refractory ascites occurs when patients no longer respond to medical therapy, a condition that affects over 100,000 patients in Europe and the United States every year, a number that is growing at approximately 10% a year. The primary treatment for ascites is paracentesis, a procedure in which a large bore needle is inserted into the patient's abdomen to remove between 5‐10 liters of ascites that has accumulated over a period of a week or two.
Related Links:
Hannover Medical School
The PeCa implant, developed at Hannover Medical School (Germany), is composed of internal shut that lies in the peritoneal cavity, a tunneled section that passes through subcutaneous tissue, and an external port to which drainage bags are connected. To test system efficacy, outcomes in 152 patients with refractory ascites, who were not candidates for transjugular intrahepatic portosystemic shunt (TIPS) and received a PeCa implant, were compared to 71 patients who received standard care, which included repeated large volume paracentesis and albumin.
The results revealed that factors associated with 90-day survival were PeCa implantation, and each point of Model for End-Stage Liver Disease (MELD) score. Hospitalizations were more common in the PeCa group, for reasons that included spontaneous bacterial peritonitis (SBP), hyponatremia, and infections other than SBP. There was no significant difference in mortality between the two groups, but there were trends in the PeCa group towards higher frequency of acute kidney injury (AKI). The study was presented at the American Association for the Study of Liver Diseases annual conference, held online during November 2021.
“Patients with refractory ascites have a very high risk for rehospitalization, AKI, and death. Our data indicate that PeCa could be a valuable new treatment option for patients with refractory ascites and contraindication for TIPS,” said study co-author and presenter Tammo Lambert Tergast, MD. “I think if we can optimize the treatment after discharge, we can also minimize the rehospitalization in these patients. However, the risk for hyponatremia and AKI has to be considered and further explored.”
Refractory ascites occurs when patients no longer respond to medical therapy, a condition that affects over 100,000 patients in Europe and the United States every year, a number that is growing at approximately 10% a year. The primary treatment for ascites is paracentesis, a procedure in which a large bore needle is inserted into the patient's abdomen to remove between 5‐10 liters of ascites that has accumulated over a period of a week or two.
Related Links:
Hannover Medical School
Latest Patient Care News
- Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
- VR Training Tool Combats Contamination of Portable Medical Equipment
- Portable Biosensor Platform to Reduce Hospital-Acquired Infections
- First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
- Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

- Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
- Next Gen ICU Bed to Help Address Complex Critical Care Needs
- Groundbreaking AI-Powered UV-C Disinfection Technology Redefines Infection Control Landscape
- Clean Hospitals Can Reduce Antibiotic Resistance, Save Lives
- Smart Hospital Beds Improve Accuracy of Medical Diagnosis
- New Fast Endoscope Drying System Improves Productivity and Traceability
- World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance
- Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER
- Portable Clinical Scale with Remote Indicator Allows for Flexible Patient Weighing Use
- Innovative and Highly Customizable Medical Carts Offer Unlimited Configuration Possibilities
- Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients
Channels
Artificial Intelligence
view channelCritical Care
view channel
Intranasal Spray to Prevent Illnesses from Respiratory Viruses
Respiratory viruses such as influenza and COVID-19 hospitalize more than one million people in the U.S. each year, with many infections spreading through close contact in households, schools, and workplaces.... Read more
AI Risk Prediction Tool Improves Treatment of Cancer Patients after Heart Attack
Cancer patients who experience a heart attack face a uniquely dangerous combination of risks, including higher chances of death, bleeding, and repeat cardiac events. Because of this complexity, they have... Read moreSurgical Techniques
view channel
New Classification System Brings Clarity to Brain Tumor Surgery Decisions
Low-grade brain tumors known as IDH-mutant gliomas (CNS WHO grade 2) are life-threatening despite their slow growth. Surgeons must balance maximal tumor removal against the risk of neurological deficits,... Read more
Boengineered Tissue Offers New Hope for Secondary Lymphedema Treatment
The rising global incidence of cancer has led to an increasing number of surgeries involving lymph node removal. While these procedures are critical for cancer staging and preventing metastatic spread,... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel
Medtronic and Mindray Expand Strategic Partnership to Ambulatory Surgery Centers in the U.S.
Mindray North America and Medtronic have expanded their strategic partnership to bring integrated patient monitoring solutions to ambulatory surgery centers across the United States. The collaboration... Read more
FDA Clearance Expands Robotic Options for Minimally Invasive Heart Surgery
Cardiovascular disease remains the world’s leading cause of death, with nearly 18 million fatalities each year, and more than two million patients undergo open-heart surgery annually, most involving sternotomy.... Read more
WHX in Dubai (formerly Arab Health) to debut specialised Biotech & Life Sciences Zone as sector growth accelerates globally
World Health Expo (WHX) in Dubai, formerly Arab Health, which takes place from 9-12 February 2026 at the Dubai Exhibition Centre (DEC), has officially announced the launch of a new dedicated Biotech &... Read more







